Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
4.730
+0.180 (3.96%)
At close: May 28, 2026, 4:00 PM EDT
4.730
0.00 (0.00%)
After-hours: May 28, 2026, 4:01 PM EDT
Atea Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
377.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 351.37M | 302.73M | 622.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Vanda Pharmaceuticals | 217.78M |
| Fennec Pharmaceuticals | 51.00M |
| Verastem | 49.59M |
| X4 Pharmaceuticals | 9.01M |
| Compass Therapeutics | 850.00K |
| YD Bio | 510.36K |
AVIR News
- 1 day ago - Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 - GlobeNewsWire
- 15 days ago - Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline - GlobeNewsWire
- 15 days ago - Atea Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
- 15 days ago - Atea Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 15 days ago - Atea Pharmaceuticals Slides: Q1 2026 - Filings
- 15 days ago - Atea Pharmaceuticals Earnings release: Q1 2026 - Filings
- 15 days ago - Atea Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 16 days ago - Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire